{"id":52345,"date":"2022-12-26T03:02:24","date_gmt":"2022-12-26T02:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/"},"modified":"2022-12-26T03:02:24","modified_gmt":"2022-12-26T02:02:24","slug":"lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/","title":{"rendered":"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca"},"content":{"rendered":"
\n

SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan\u201d (“i2.JP”; Website: https:\/\/www.i2jp.net\/en\/index.html<\/a>), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).\n<\/p>\n

<\/a><\/p>\n

\ni2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.\n<\/p>\n

\nLightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.\n<\/p>\n

\nBy leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLightnix Inc.
\n
Akihiro ISUMI, General Manager
\n
+81-48-951-3637
\n
info@lightnix.jp<\/a>
https:\/\/www.lightnix.jp\/en\/<\/a><\/span>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan\u201d (“i2.JP”; Website: https:\/\/www.i2jp.net\/en\/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii). i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52345","6":"format-standard","7":"category-industry"},"yoast_head":"\nLightnix decided to participate as a partner company in i2.JP led by AstraZeneca - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan\u201d (“i2.JP”; Website: https:\/\/www.i2jp.net\/en\/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii). i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-26T02:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221222005584\/en\/1672359\/21\/logo_org.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca\",\"datePublished\":\"2022-12-26T02:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/\"},\"wordCount\":174,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005584\\\/en\\\/1672359\\\/21\\\/logo_org.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/\",\"name\":\"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005584\\\/en\\\/1672359\\\/21\\\/logo_org.jpg\",\"datePublished\":\"2022-12-26T02:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005584\\\/en\\\/1672359\\\/21\\\/logo_org.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005584\\\/en\\\/1672359\\\/21\\\/logo_org.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca - Pharma Trend","og_description":"SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan\u201d (“i2.JP”; Website: https:\/\/www.i2jp.net\/en\/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii). i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-26T02:02:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221222005584\/en\/1672359\/21\/logo_org.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca","datePublished":"2022-12-26T02:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/"},"wordCount":174,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221222005584\/en\/1672359\/21\/logo_org.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/","url":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/","name":"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221222005584\/en\/1672359\/21\/logo_org.jpg","datePublished":"2022-12-26T02:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221222005584\/en\/1672359\/21\/logo_org.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221222005584\/en\/1672359\/21\/logo_org.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lightnix-decided-to-participate-as-a-partner-company-in-i2-jp-led-by-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52345"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52345\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}